Anaptysbio, INC 10-Q quarterly reports

AnaptysBio reports first-quarter 2026 financial results, detailing a net loss of $52.9 million and the successful separation of its First Tracks Biotherapeutics business.

AnaptysBio reported a significant increase in collaboration revenue for Q3 2025, driven by Jemperli sales milestones, while advancing plans to separate into two independent public companies by year-end 2026.

AnaptysBio reports increased collaboration revenue and reduced operating loss in Q2 2025, driven by positive rosnilimab data and new partnerships, despite a significant cash burn and a partnered trial setback.

AnaptysBio's Q1 2025 results show increased collaboration revenue driven by royalties, progress in rosnilimab clinical trials, and a new licensing agreement with Vanda Pharmaceuticals.

AnaptysBio's Q3 2024 results show a significant increase in collaboration revenue driven by milestone and royalty payments, alongside ongoing clinical development of key product candidates.

AnaptysBio's Q2 2024 results show increased collaboration revenue and R&D expenses, alongside a net loss, as the company advances its clinical programs.

AnaptysBio's Q1 2024 report reveals increased collaboration revenue and ongoing clinical development of key immunology therapeutics, alongside a net loss.